What is Nimble Science?
Nimble Science is a pioneering health technology firm dedicated to revolutionizing gastrointestinal care through its innovative SIMBA GI Platform. The company specializes in high-fidelity small intestine sampling, providing researchers and clinicians with comprehensive multi-omic datasets that were previously difficult to obtain. By mapping the entire gastrointestinal tract, Nimble Science empowers biopharma companies and nutrition researchers to validate microbiome changes with unprecedented precision. This technological edge is essential for the development of next-generation treatments, including advanced fecal transplant therapies and personalized nutritional interventions. Their market position is defined by a unique ability to bridge the gap between complex biological data and actionable therapeutic insights, serving as a vital partner for organizations aiming to improve patient health outcomes through evidence-based microbiome science.
How much funding has Nimble Science raised?
Nimble Science has raised a total of $2M across 1 funding round:
Other Financing Round
$2M
Other Financing Round (2023): $2M with participation from Bluesky Equities, Fusion Fund, and Threshold Impact
Key Investors in Nimble Science
Bluesky Equities
Bluesky Equities is a private investment management firm based in Calgary, Canada, that maintains a long-term perspective on diverse holdings including technology, energy, and venture capital.
Fusion Fund
Fusion Fund is a venture capital firm specializing in early-stage startups that leverage technical or data-driven advantages, particularly within the healthcare and enterprise AI sectors.
Threshold Impact
Threshold Impact focuses on sustainable and profitable impact investing, supporting ventures in medical innovation and technology that aim to generate positive global outcomes.
What's next for Nimble Science?
With this major strategic investment, Nimble Science is poised to deepen its penetration into the biopharma research market. The company's roadmap focuses on scaling the deployment of the SIMBA GI Platform to support larger clinical trials and longitudinal studies. By leveraging the expertise of its investor base, the firm intends to refine its data analytics pipeline, ensuring that its multi-omic insights remain at the forefront of medical innovation. Future growth will likely center on strategic partnerships that integrate their sampling technology into broader drug discovery workflows, ultimately aiming to standardize the role of microbiome analysis in routine therapeutic development and gastrointestinal health management.
See full Nimble Science company page
